On June 19 (Wednesday), we will organize a group interview tour for Chinese and foreign journalists to AstraZeneca Global R&D China Center, Bayer (China) Co., Ltd. and Shanghai Intellectual Property Administrative Service Center. The specific arrangements are as follows:

12:45 Assemble at the West Gate, 200, People’s Avenue

13:30 - 14:30 Interview with AstraZeneca Global R&D China Center

(Yingkai Cultural Plaza, 88, North Xizang Road, Jing’an District)

15:00 - 16:00 Interview with Bayer (China) Co., Ltd

(399, West Haiyang Road, Pudong New Area)

16:30 - 17:15 Interview with Shanghai Intellectual Property Administrative Service Center

(340, Shibocun Road, Nanmatou Sub-district, Pudong New Area)

Please send media, name and phone number to touchshanghai@126.com before 17:00 by June 18, 2024.

Contact: Lu Yanbo 15221690488

        Huang Shanjie 18918889674

< style="text-align:right;layout-grid-mode:char; mso-layout-grid-align:none"> 

< style="text-align:right;layout-grid-mode:char; mso-layout-grid-align:none">Information Office of Shanghai Municipality

< style="text-align:right;layout-grid-mode:char; mso-layout-grid-align:none"> 

Introduction

 

1. AstraZeneca Global R&D China Center

AstraZeneca is a leading global biopharmaceutical company dedicated to the development, manufacturing, and marketing of prescription medicines, with a primary focus on oncology, rare diseases, and cardiovascular, renal, metabolic, respiratory, and immunological conditions. Headquartered in Cambridge, UK, AstraZeneca operates in over 100 countries, providing innovative medicines to millions of patients worldwide.

Since entering China in 1993, AstraZeneca has concentrated on therapeutic areas with urgent needs among Chinese patients, including oncology, cardiovascular, renal, metabolic, respiratory, digestive, rare diseases, vaccines/antibodies, and autoimmunity. The company’s China headquarters and Global R&D China Center are located in Shanghai, supported by global production and supply bases in Wuxi, Taizhou, and Qingdao, delivering high-quality drugs to more than 70 markets worldwide.

2. Bayer (China) Co., Ltd.

Bayer, a Germany-based innovative company with over 160 years of history, excels in healthcare and agritech. In fiscal 2023, Bayer employed approximately 99,700 people, generated sales of EUR 47.6 billion, and invested EUR 5.4 billion in research and development, excluding special projects.

Bayer has been established in China since 1882, marking over 140 years of presence in the country. China remains one of Bayer’s most significant strategic markets globally. In fiscal 2023, Bayer generated EUR 3.524 billion in sales in China and employed nearly 8,000 people.

3. Shanghai Intellectual Property Administrative Service Center

As the joint external government service window for the China National Intellectual Property Administration Shanghai Service and the Shanghai Intellectual Property Administration, the Shanghai Intellectual Property Administrative Service Center has consistently adhered to the principles of “administration according to law, quality assurance, and warm service.” Our goal is to “shape a first-class image, achieve first-class performance, optimize the business environment, and support the development of intellectual property rights.” We are dedicated to implementing the mission of “convenience for the people, benefit for the people, and service to the people.”

To further optimize the business environment, the Shanghai Intellectual Property Government Service Hall has introduced a series of convenient measures, including unified online services that allow applications to be submitted without the need for onsite documentation, as well as uninterrupted services during the lunch break. These initiatives align with our service concept of people-friendliness, aimed at “reducing time, materials, and trips.” By implementing these measures, we continuously improve service efficiency and innovate service concepts.